Ritobegron
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Ritobegron
- Accession Number
- DB12080
- Description
Ritobegron is under investigation in clinical trial NCT02256735 (Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Ritobegron (DB12080)
- Weight
- Average: 373.449
Monoisotopic: 373.188922973 - Chemical Formula
- C21H27NO5
- Synonyms
- Ritobegron
- External IDs
- KUC-7483
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide The risk or severity of adverse effects can be increased when Ritobegron is combined with Abaloparatide. Acebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with Ritobegron. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Ritobegron. Acemetacin The risk or severity of hypertension can be increased when Ritobegron is combined with Acemetacin. Acetazolamide Acetazolamide may decrease the excretion rate of Ritobegron which could result in a higher serum level. Acetophenazine Acetophenazine may decrease the stimulatory activities of Ritobegron. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Ritobegron. Aclidinium The risk or severity of Tachycardia can be increased when Aclidinium is combined with Ritobegron. Acrivastine Ritobegron may decrease the sedative and stimulatory activities of Acrivastine. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Ritobegron. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Acids, Acyclic
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic beta-3 Receptor Agonists
- Adrenergic beta-Agonists
- Agents producing tachycardia
- Agents that produce hypertension
- Amines
- Amphetamines
- Drugs for Urinary Frequency and Incontinence
- Ethylamines
- Fatty Acids
- Fatty Acids, Volatile
- Lipids
- Neurotransmitter Agents
- Phenethylamines
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Sympathomimetics
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenoxyacetic acid derivatives
- Direct Parent
- Phenoxyacetic acid derivatives
- Alternative Parents
- Phenethylamines / Phenylpropanes / p-Xylenes / Phenoxy compounds / Phenol ethers / 1-hydroxy-2-unsubstituted benzenoids / Alkyl aryl ethers / Aralkylamines / 1,2-aminoalcohols / Amino acids show 8 more
- Substituents
- 1,2-aminoalcohol / 1-hydroxy-2-unsubstituted benzenoid / Alcohol / Alkyl aryl ether / Amine / Amino acid / Amino acid or derivatives / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound show 22 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- LD86RKR53M
- CAS number
- 255734-04-4
- InChI Key
- VMMYRRFPMAGXNP-BTYIYWSLSA-N
- InChI
- InChI=1S/C21H27NO5/c1-13-11-19(27-12-20(24)25)14(2)10-17(13)8-9-22-15(3)21(26)16-4-6-18(23)7-5-16/h4-7,10-11,15,21-23,26H,8-9,12H2,1-3H3,(H,24,25)/t15-,21-/m0/s1
- IUPAC Name
- 2-[4-(2-{[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)-2,5-dimethylphenoxy]acetic acid
- SMILES
- C[C@H](NCCC1=C(C)C=C(OCC(O)=O)C(C)=C1)[C@H](O)C1=CC=C(O)C=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 9820882
- PubChem Substance
- 347828386
- ChemSpider
- 7996631
- ChEMBL
- CHEMBL2107773
- ZINC
- ZINC000072266295
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Urinary Bladder, Overactive 1 3 Withdrawn Treatment Urinary Bladder, Overactive 1 2 Completed Treatment Urinary Bladder, Overactive 1 1 Completed Treatment Healthy Volunteers 6 1 Completed Treatment Spinal Cord Injuries (SCI) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0103 mg/mL ALOGPS logP 1.79 ALOGPS logP 0.9 ChemAxon logS -4.6 ALOGPS pKa (Strongest Acidic) 3.73 ChemAxon pKa (Strongest Basic) 10.01 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 99.02 Å2 ChemAxon Rotatable Bond Count 9 ChemAxon Refractivity 103.67 m3·mol-1 ChemAxon Polarizability 41.25 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on October 20, 2016 21:19 / Updated on February 21, 2021 18:53